コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 omatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR
3 of TRAP-stained cells was higher in the estrogen-deficient group than in estrogen-sufficient group at 30 days post-extra
4 endships in pairs of students who were assigned to the same group than in pairs from different groups (short-term effects
5 elative risk, 0.81; 97.5% CI, 0.67 to 0.96) and in the 5-mg group than in the 20-mg group (relative risk, 0.71; 97.5% CI,
6 respectively; the risk was significantly lower in the 10-mg group than in the 20-mg group (relative risk, 0.81; 97.5% CI,
7 e upadacitinib group, and more patients in the upadacitinib group than in the abatacept group had elevated hepatic aminot
8 Complications were more common in the antibiotics group than in the appendectomy group (8.1 vs. 3.5 per 100 par
9 at 30 days, the event rate was higher in the Portico valve group than in the commercial valve group (52 [13.8%] vs 35 [9
10 EF-5 <= 11) at 12 months after surgery was lower in the Exp-group than in the Con-group (12.5% vs 34.2%, P = 0.023); Exp-
11 e incidence of ejaculation dysfunction was lower in the Exp-group than in the Con-group at 12 months after surgery (10.0%
13 The time to decannulation was shorter in the intervention group than in the control group (median, 6 days [interquartil
14 sion-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 m
17 o baseline on POD1 was also significantly higher in the NMS group than in the HMS group (22.5% vs. 3.0%, P < 0.001).
18 response value in patients with LTBI was higher in the KTR group than in the KTC group (1.85 vs 1.06 IU/mL, P = .046).
19 RBC units transfused was lower in the restrictive-strategy group than in the liberal-strategy group (mean, 2.73 units [s
20 Splenic uptake was higher in the AML/MDS group than in the lymphoma group (P <= 0.05) or the multiple
21 he exception was greater splenic uptake in the leukemia/MDS group than in the lymphoma or multiple myeloma group.
22 Parenchymal calcification was more common in the XDR group than in the MDR group (64.7% and 28.6%, respectively) w
23 ary complications (leak and stricture) were higher in PLDRH group than in the ODRH group (8% vs. 3%), but it failed to re
24 eved in a greater proportion of patients in the closed-loop group than in the open-loop group at 3 months (51 [82.3%] of
25 rum miR-375 was significantly lower in the peritoneal pouch group than in the peritoneal cavity group.
26 e at week 12 was significantly greater in the difelikefalin group than in the placebo group (37.1% [observed data: 64 of
27 sion burden of at least 33% was greater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the
28 More participants in the liraglutide group than in the placebo group had gastrointestinal adverse
29 er incidence of readmission or death in the chemoprevention group than in the placebo group was restricted to the interve
30 fusion burden was significantly greater in the luspatercept group than in the placebo group, and few adverse events led t
34 e 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group.
35 Side effects were more reported in the HCQ group than in the SC (RR = 3.14, 95% CI 1.58-6.24, I(2) = 0).
36 (P =0.007 0.023 and 0.011, respectively) in the acupuncture group than in the sham acupuncture group.
37 inful symptomatology was reported less frequently in the EE group than in the sham group at 3-day follow-up (P = 0.008).
39 At 5 years, more patients in the TAVR group than in the surgery group had at least mild paravalvula
40 disease-free survival was significantly higher in the T-DM1 group than in the trastuzumab arm (hazard ratio, 0.50; 95% CI
41 but the sensitivity of the IgG ELISA was much lower in this group than in those with a multitypic profile.
42 , crazy-paving pattern was more predominant in non-survivor group than survivor group (39.0% vs. 12.0%, p < 0.001).
43 Unexpectedly, this ratio was higher in the AOM/DSS group than that determined in other males and the AOM/DSS/E2
44 mance gain over a 12-h interval including sleep in a reward group than that in a no-reward group.
45 s, sleep quality was assessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7
46 ian time to the first relapse was longer in the tocilizumab group than the azathioprine group (78.9 weeks [IQR 58.3-90.6]
47 iencing adverse events was higher in the hydroxychloroquine group than the control group (66 [16.2%] versus 46 [10.9%], r
49 me to parasitemia was significantly shorter in the sero-low group than the sero-high group (9 days [interquartile range {
50 erage consumption was significantly higher among high-mPESS group than their low-mPESS counterparts, especially for hard